메뉴 건너뛰기




Volumn 20, Issue 6, 2011, Pages 517-522

Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: Evidence from the Japan Alteplase Clinical Trial (J-ACT)

Author keywords

Acute ischemic stroke; acute stroke outcome; clinical outcome; clinical trial; thrombolysis; thrombolysis associated hemorrhage; tissue plasminogen activator

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; GLUCOSE;

EID: 81155153635     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2010.04.001     Document Type: Article
Times cited : (8)

References (20)
  • 1
    • 33745963843 scopus 로고    scopus 로고
    • Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)
    • DOI 10.1161/01.STR.0000227191.01792.e3, PII 0000767020060700000049
    • T. Yamaguchi, E. Mori, and K. Minematsu Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT) Stroke 37 2006 1810 1815 (Pubitemid 44297734)
    • (2006) Stroke , vol.37 , Issue.7 , pp. 1810-1815
    • Yamaguchi, T.1    Mori, E.2    Minematsu, K.3    Nakagawara, J.4    Hashi, K.5    Saito, I.6    Shinohara, Y.7
  • 2
    • 0028783948 scopus 로고
    • Tissue plasminogen activator for acute ischemic stroke
    • National Institute Of Neurological Disorders And Stroke Rt-Pa Stroke Study Group
    • National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
    • (1995) N Engl J Med , vol.333 , pp. 1581-1587
  • 3
    • 0343990052 scopus 로고    scopus 로고
    • Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial
    • Ninds T-Pa Stroke Study Group
    • NINDS t-PA Stroke Study Group Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial Stroke 28 1997 2119 2125
    • (1997) Stroke , vol.28 , pp. 2119-2125
  • 5
    • 0346340049 scopus 로고    scopus 로고
    • CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator
    • C.A. Molina, A.V. Alexandrov, and A.M. Demchuk CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator Stroke 35 2004 151 157
    • (2004) Stroke , vol.35 , pp. 151-157
    • Molina, C.A.1    Alexandrov, A.V.2    Demchuk, A.M.3
  • 6
    • 0034161354 scopus 로고    scopus 로고
    • Intravenous tissue-type plasminogen activator for treatment of acute stroke: The standard treatment with alteplase to reverse stroke (STARS) study
    • G.W. Albers, V.E. Bates, and W.M. Clark Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study JAMA 283 2000 1145 1150 (Pubitemid 30126602)
    • (2000) Journal of the American Medical Association , vol.283 , Issue.9 , pp. 1145-1150
    • Albers, G.W.1    Bates, V.E.2    Clark, W.M.3    Bell, R.4    Verro, P.5    Hamilton, S.A.6
  • 7
    • 39349090620 scopus 로고    scopus 로고
    • Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial
    • DOI 10.1161/STROKEAHA.107.492330, PII 0000767020080200000027
    • M. Yong, and M. Kaste Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial Stroke 39 2008 366 372 (Pubitemid 351619457)
    • (2008) Stroke , vol.39 , Issue.2 , pp. 366-372
    • Yong, M.1    Kaste, M.2
  • 8
    • 58149357100 scopus 로고    scopus 로고
    • SITS-MOST Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials
    • N. Wahlgren, N. Ahmed, and N. Eriksson SITS-MOST Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials Stroke 39 2008 3316 3322
    • (2008) Stroke , vol.39 , pp. 3316-3322
    • Wahlgren, N.1    Ahmed, N.2    Eriksson, N.3
  • 9
    • 54049111024 scopus 로고    scopus 로고
    • Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial
    • M. Yong, and M. Kaste Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial Stroke 39 2008 2749 2755
    • (2008) Stroke , vol.39 , pp. 2749-2755
    • Yong, M.1    Kaste, M.2
  • 10
    • 0343118114 scopus 로고    scopus 로고
    • T-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
    • The N.I.N.D.S.
    • N.I.N.D.S. The t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke Stroke 28 1997 2109 2118
    • (1997) Stroke , vol.28 , pp. 2109-2118
  • 11
    • 33645800351 scopus 로고    scopus 로고
    • Extent of early ischemic changes on computed tomography (CT) before thrombolysis: Prognostic value of the Alberta Stroke Program Early CT Score in ECASS II
    • I. Dzialowski, M.D. Hill, and S.B. Coutts Extent of early ischemic changes on computed tomography (CT) before thrombolysis: Prognostic value of the Alberta Stroke Program Early CT Score in ECASS II Stroke 37 2006 973 978
    • (2006) Stroke , vol.37 , pp. 973-978
    • Dzialowski, I.1    Hill, M.D.2    Coutts, S.B.3
  • 12
    • 0030950928 scopus 로고    scopus 로고
    • Hemorrhagic transformation in acute ischemic stroke: Potential contributing factors in the European Cooperative Acute Stroke Study
    • V. Larrue, R. von Kummer, and G. Zoppo Hemorrhagic transformation in acute ischemic stroke: Potential contributing factors in the European Cooperative Acute Stroke Study Stroke 28 1997 957 960 (Pubitemid 27209140)
    • (1997) Stroke , vol.28 , Issue.5 , pp. 957-960
    • Larrue, V.1    Von Kummer, R.2    Del Zoppo, G.3    Bluhmki, E.4
  • 13
    • 0035130531 scopus 로고    scopus 로고
    • Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
    • V. Larrue, R. von Kummer, and A. Muller Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II) Stroke 32 2001 438 441 (Pubitemid 32155231)
    • (2001) Stroke , vol.32 , Issue.2 , pp. 438-441
    • Larrue, V.1    Von Kummer, R.2    Muller, A.3    Bluhmki, E.4
  • 14
    • 0034643745 scopus 로고    scopus 로고
    • Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy
    • P.A. Barber, A.M. Demchuk, and J. Zhang Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy Lancet 355 2000 1670 1674 (Pubitemid 30248478)
    • (2000) Lancet , vol.355 , Issue.9216 , pp. 1670-1674
    • Barber, P.A.1    Demchuk, A.M.2    Zhang, J.3    Buchan, A.M.4
  • 16
    • 0026665797 scopus 로고
    • Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke
    • R. von Kummer, and W. Hacke Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke Stroke 23 1992 646 652
    • (1992) Stroke , vol.23 , pp. 646-652
    • Von Kummer, R.1    Hacke, W.2
  • 17
    • 0026736173 scopus 로고
    • Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
    • E. Mori, Y. Yoneda, and M. Tabuchi Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke Neurology 42 1992 976 982
    • (1992) Neurology , vol.42 , pp. 976-982
    • Mori, E.1    Yoneda, Y.2    Tabuchi, M.3
  • 19
    • 70350527974 scopus 로고    scopus 로고
    • Arterial occlusion sites on MRA influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischemic stroke
    • T. Nakashima, K. Toyoda, and M. Koga Arterial occlusion sites on MRA influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischemic stroke Int J Stroke 4 2009 425 431
    • (2009) Int J Stroke , vol.4 , pp. 425-431
    • Nakashima, T.1    Toyoda, K.2    Koga, M.3
  • 20
    • 77649088870 scopus 로고    scopus 로고
    • Japan Alteplase Clinical Trial II (J-ACT II) Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II)
    • E. Mori, K. Minematsu, and J. Nakagawara Japan Alteplase Clinical Trial II (J-ACT II) Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II) Stroke 41 2010 461 465
    • (2010) Stroke , vol.41 , pp. 461-465
    • Mori, E.1    Minematsu, K.2    Nakagawara, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.